Cite
HARVARD Citation
Gharaibeh, M. et al. (2017). Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. Journal of medical economics. pp. 345-352. [Online].